All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Caribou Biosciences, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi and Thermo Fisher Scientific and supported through independent educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
FDA clears investigational new drug application for ‘OncoMimic’ based immunotherapy EO2463
On March 24, 2021, it was announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for EO2463, an ‘OncoMimic’ based immunotherapy being investigated for the treatment of indolent non-Hodgkin lymphoma.
A phase I/II clinical trial (NCT04669171), expected to be initiated in Q2 2021, will evaluate the safety, tolerability, and efficacy of EO2463 as a monotherapy and in combination with standard of care (rituximab, and rituximab plus lenalidomide) in 60 patients with follicular lymphoma and marginal zone lymphoma.
EO2463
EO2463 is a novel investigational immunotherapy that comprises four peptides, derived from bacteria present in the gut microbiome, which mimic B lymphocyte-specific lineage markers. The ‘OncoMimic’ based therapy is designed to induce full depletion of the malignant B lymphocytes that are enriched in indolent non-Hodgkin lymphoma.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In patients with R/R LBCL who progress after CAR‑T, which of the following data would most strengthen your confidence in considering BV+R2?